hotspot -WSS

hotspot

author：leisure time 2025-09-07 00:17:25 - browse：21

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Three issues to watch in global health in 2024

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

How I ended up pumping milk in a bathroom stall at JPM 2024

Timeline: Special counsel's investigation into Trump's handling of classified documents

TB outbreak tied to bone grafts underscores testing shortcomings

Genentech weighs delaying cancer therapy after drug pricing law

Fauci’s Covid grilling leads GOP to weigh foreign research rules

entertainment

hotspot

hotspot

Alkermes shareholders re

Faced with fears of OxyContin misuse, sales reps touted its safety

Drug repurposing or repositioning? The language matters

TB outbreak tied to bone grafts underscores testing shortcomings

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

DeSantis can now import cheaper drugs. But will Biden get credit?

Medicare proposal to cover medical devices draws a mixed reaction

As JPM 2024 winds down, some health tech firms project optimism

hotspot

TB outbreak tied to bone grafts underscores testing shortcomings

Timeline: Special counsel's investigation into Trump's handling of classified documents

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Timeline: Special counsel's investigation into Trump's handling of classified documents

New England Journal of Medicine addresses racist history, slavery

Heart disease and mental health: A look at cardiac psychology

hotspot

focus

entertainment

focus